Base de dados : MEDLINE
Pesquisa : E01.370.350.700.500 [Categoria DeCS]
Referências encontradas : 26835 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2684 ir para página                         

  1 / 26835 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29318276
[Au] Autor:Plevritis SK; Munoz D; Kurian AW; Stout NK; Alagoz O; Near AM; Lee SJ; van den Broek JJ; Huang X; Schechter CB; Sprague BL; Song J; de Koning HJ; Trentham-Dietz A; van Ravesteyn NT; Gangnon R; Chandler Y; Li Y; Xu C; Ergun MA; Huang H; Berry DA; Mandelblatt JS
[Ad] Endereço:Departments of Radiology and Biomedical Data Science, School of Medicine, Stanford University, Stanford, California.
[Ti] Título:Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
[So] Source:JAMA;319(2):154-164, 2018 01 09.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden. Objective: To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions by molecular subtype based on estrogen-receptor (ER) and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu). Design, Setting, and Participants: Six Cancer Intervention and Surveillance Network (CISNET) models simulated US breast cancer mortality from 2000 to 2012 using national data on plain-film and digital mammography patterns and performance, dissemination and efficacy of ER/ERBB2-specific treatment, and competing mortality. Multiple US birth cohorts were simulated. Exposures: Screening mammography and treatment. Main Outcomes and Measures: The models compared age-adjusted, overall, and ER/ERBB2-specific breast cancer mortality rates from 2000 to 2012 for women aged 30 to 79 years relative to the estimated mortality rate in the absence of screening and treatment (baseline rate); mortality reductions were apportioned to screening and treatment. Results: In 2000, the estimated reduction in overall breast cancer mortality rate was 37% (model range, 27%-42%) relative to the estimated baseline rate in 2000 of 64 deaths (model range, 56-73) per 100 000 women: 44% (model range, 35%-60%) of this reduction was associated with screening and 56% (model range, 40%-65%) with treatment. In 2012, the estimated reduction in overall breast cancer mortality rate was 49% (model range, 39%-58%) relative to the estimated baseline rate in 2012 of 63 deaths (model range, 54-73) per 100 000 women: 37% (model range, 26%-51%) of this reduction was associated with screening and 63% (model range, 49%-74%) with treatment. Of the 63% associated with treatment, 31% (model range, 22%-37%) was associated with chemotherapy, 27% (model range, 18%-36%) with hormone therapy, and 4% (model range, 1%-6%) with trastuzumab. The estimated relative contributions associated with screening vs treatment varied by molecular subtype: for ER+/ERBB2-, 36% (model range, 24%-50%) vs 64% (model range, 50%-76%); for ER+/ERBB2+, 31% (model range, 23%-41%) vs 69% (model range, 59%-77%); for ER-/ERBB2+, 40% (model range, 34%-47%) vs 60% (model range, 53%-66%); and for ER-/ERBB2-, 48% (model range, 38%-57%) vs 52% (model range, 44%-62%). Conclusions and Relevance: In this simulation modeling study that projected trends in breast cancer mortality rates among US women, decreases in overall breast cancer mortality from 2000 to 2012 were associated with advances in screening and in adjuvant therapy, although the associations varied by breast cancer molecular subtype.
[Mh] Termos MeSH primário: Neoplasias da Mama/mortalidade
Detecção Precoce de Câncer
Mamografia
Modelos Estatísticos
[Mh] Termos MeSH secundário: Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/terapia
Feminino
Seres Humanos
Mamografia/métodos
Mortalidade/tendências
Receptor ErbB-2
Receptores Estrogênicos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Receptors, Estrogen); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180311
[Lr] Data última revisão:
180311
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.19130


  2 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29342379
[Au] Autor:Trivedi AN; Leyva B; Lee Y; Panagiotou OA; Dahabreh IJ
[Ad] Endereço:From the Departments of Health Services, Policy and Practice (A.N.T., B.L., Y.L., O.A.P., I.J.D.), and Epidemiology (I.J.D.), Brown University School of Public Health, and the Providence Veterans Affairs Medical Center (A.N.T.) - both in Providence, RI.
[Ti] Título:Elimination of Cost Sharing for Screening Mammography in Medicare Advantage Plans.
[So] Source:N Engl J Med;378(3):262-269, 2018 01 18.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The Affordable Care Act (ACA) required most insurers and the Medicare program to eliminate cost sharing for screening mammography. METHODS: We conducted a difference-in-differences study of biennial screening mammography among 15,085 women 65 to 74 years of age in 24 Medicare Advantage plans that eliminated cost sharing to provide full coverage for screening mammography, as compared with 52,035 women in 48 matched control plans that had and maintained full coverage. RESULTS: In plans that eliminated cost sharing, adjusted rates of biennial screening mammography increased from 59.9% (95% confidence interval [CI], 54.9 to 65.0) in the 2-year period before cost-sharing elimination to 65.4% (95% CI, 61.8 to 69.0) in the 2-year period thereafter. In control plans, the rates of biennial mammography were 73.1% (95% CI, 69.2 to 77.0) and 72.8% (95% CI, 69.7 to 76.0) during the same periods, yielding a difference in differences of 5.7 percentage points (95% CI, 3.0 to 8.4). The difference in differences was 9.8 percentage points (95% CI, 4.5 to 15.2) among women living in the areas with the highest quartile of educational attainment versus 4.3 percentage points (95% CI, 0.2 to 8.4) among women in the lowest quartile. As indicated by the difference-in-differences estimates, after the elimination of cost sharing, the rate of biennial mammography increased by 6.5 percentage points (95% CI, 3.7 to 9.4) for white women and 8.4 percentage points (95% CI, 2.5 to 14.4) for black women but was almost unchanged for Hispanic women (0.4 percentage points; 95% CI, -7.3 to 8.1). CONCLUSIONS: The elimination of cost sharing for screening mammography under the ACA was associated with an increase in rates of use of this service among older women for whom screening is recommended. The effect was attenuated among women living in areas with lower educational attainment and was negligible among Hispanic women. (Funded by the National Institute on Aging.).
[Mh] Termos MeSH primário: Custo Compartilhado de Seguro
Mamografia/utilização
Medicare Part C/economia
Patient Protection and Affordable Care Act
[Mh] Termos MeSH secundário: Idoso
Detecção Precoce de Câncer/utilização
Grupos Étnicos
Feminino
Seres Humanos
Mamografia/economia
Medicare
Fatores Socioeconômicos
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMsa1706808


  3 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29204896
[Au] Autor:Streng M; Ignatov A; Reinisch M; Costa SD; Eggemann H
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Magdeburg, Magdeburg, Germany.
[Ti] Título:A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study.
[So] Source:J Cancer Res Clin Oncol;144(2):381-387, 2018 Feb.
[Is] ISSN:1432-1335
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Precise presurgical diagnosis of tumour size is essential for adequate treatment of male breast cancer (MBC). This study is aimed to compare the accuracy of clinical measurement (CE), ultrasound (US) and mammography (MG) for preoperative estimation of tumour size. METHODS: This study was conducted as a prospective, multicentre register study. One hundred and twenty-nine male patients with invasive breast cancer were included. CE, US and MG were performed in 107, 110 and 75 patients, respectively, and the estimated tumour size was compared with the histopathological (HP) tumour size. RESULTS: All methods tended to underestimate the HP tumour size. None of the methods were significantly more accurate than the others in determining the maximal tumour diameter. The sensitivity within 5 mm tolerance for US was 65.5%, which was better than for MG (61.3%) and CE (56.6%). In the group of patients with pT2 tumours, MG showed significantly better accuracy than US. The measurements obtained with each method were significantly correlated with the HP measurements. The highest correlation coefficient was observed for MG (0.788), followed by US (0.741) and CE (0.671). CONCLUSIONS: Our data demonstrate that MG and US have similar accuracy with regard to tumour size estimation. US assessment showed the highest sensitivity in determining tumour size, followed by MG and CE. However, MG demonstrated a significant advantage for estimating the real tumour size for pT2 tumours compared to US or CE.
[Mh] Termos MeSH primário: Neoplasias da Mama Masculina/diagnóstico
Neoplasias da Mama Masculina/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama Masculina/diagnóstico por imagem
Neoplasias da Mama Masculina/epidemiologia
Alemanha/epidemiologia
Seres Humanos
Masculino
Mamografia
Meia-Idade
Palpação
Estudos Prospectivos
Sistema de Registros
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1007/s00432-017-2554-8


  4 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464481
[Au] Autor:Hack CC; Stoll MJ; Jud SM; Heusinger K; Adler W; Haeberle L; Ganslandt T; Heindl F; Schulz-Wendtland R; Cavallaro A; Uder M; Beckmann MW; Fasching PA; Bayer CM
[Ad] Endereço:Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen/European Metropolitan Area Nuremberg (CCC ER-EMN), Erlangen, Germany.
[Ti] Título:Correlation of mammographic density and serum calcium levels in patients with primary breast cancer.
[So] Source:Cancer Med;6(6):1473-1481, 2017 Jun.
[Is] ISSN:2045-7634
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Percentage mammographic breast density (PMD) is one of the most important risk factors for breast cancer (BC). Calcium, vitamin D, bisphosphonates, and denosumab have been considered and partly confirmed as factors potentially influencing the risk of BC. This retrospective observational study investigated the association between serum calcium level and PMD. A total of 982 BC patients identified in the research database at the University Breast Center for Franconia with unilateral BC, calcium and albumin values, and mammogram at the time of first diagnosis were included. PMD was assessed, using a semiautomated method by two readers. Linear regression analyses were conducted to investigate the impact on PMD of the parameters of serum calcium level adjusted for albumin level, and well-known clinical predictors such as age, body mass index (BMI), menopausal status and confounder for serum calcium like season in which the BC was diagnosed. Increased calcium levels were associated with reduced PMD (P = 0.024). Furthermore, PMD was inversely associated with BMI (P < 0.001) and age (P < 0.001). There was also an association between PMD and menopausal status (P < 0.001). The goodness-of-fit of the regression model was moderate. This is the first study assessing the association between serum calcium level and PMD. An inverse association with adjusted serum calcium levels was observed. These findings add to previously published data relating to vitamin D, bisphosphonates, denosumab, and the RANK/RANKL signaling pathway in breast cancer risk and prevention.
[Mh] Termos MeSH primário: Densidade da Mama
Neoplasias da Mama/sangue
Neoplasias da Mama/diagnóstico por imagem
Cálcio/sangue
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Mamografia
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
SY7Q814VUP (Calcium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1002/cam4.1066


  5 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452044
[Au] Autor:Luckmann R; White MJ; Costanza ME; Frisard CF; Cranos C; Sama S; Yood R
[Ad] Endereço:Department of Family Medicine and Community Health, University of Massachusetts Medical School, 55 Lave Ave. N, Worcester, MA, 01655, USA. LuckmanR@ummhc.org.
[Ti] Título:Implementation and process evaluation of three interventions to promote screening mammograms delivered for 4 years in a large primary care population.
[So] Source:Transl Behav Med;7(3):547-556, 2017 Sep.
[Is] ISSN:1613-9860
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The optimal form of outreach to promote repeated, on time screening mammograms in primary care has not been established. The purpose of this study is to assess the implementation process and process outcomes for three interventions for promoting biannual screening mammography in a randomized trial. In a large urban primary care practice over a 4-year period, we randomized women aged 40-85 and eligible for mammograms to three interventions: reminder letter only (LO), reminder letter + reminder call (RC), and reminder letter + counseling call (CC). We tracked information system development, staff training, patient and provider recruitment, reach, dose delivered and received, fidelity, and context measures. Ninety-three of 95 providers approved participation by 80% (23,999) of age-eligible patients, of whom only 207 (0.9%) opted not to receive any intervention. Of 9161 initial reminder letters mailed to women coming due or overdue for mammograms, 0.8% were undeliverable. Of women in the RC and CC arms unresponsive to the first reminder letter (n = 3982), 71.4% were called and reached, and of those, 49.1% scheduled a mammogram. Only 33.4% of women reached in the CC arm received full counseling, and women in the CC arm were less likely to schedule a mammogram than those in the RC arm. Implementing mail and telephone mammography reminders is feasible and acceptable in a large urban practice and reaches a majority of patients. Many schedule a mammogram when reached. A reminder letter followed by a simple reminder call if needed may be the optimal approach to promoting screening mammograms.
[Mh] Termos MeSH primário: Aconselhamento
Detecção Precoce de Câncer/métodos
Promoção da Saúde/métodos
Mamografia
Atenção Primária à Saúde
Sistemas de Alerta
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/prevenção & controle
Feminino
Implementação de Plano de Saúde
Política de Saúde
Seres Humanos
Meia-Idade
Atenção Primária à Saúde/métodos
Avaliação de Programas e Projetos de Saúde
Software
Telefone
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1007/s13142-017-0497-x


  6 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28742062
[Au] Autor:Moore CS; Wood TJ; Saunderson JR; Beavis AW
[Ad] Endereço:Radiation Physics Department, Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Hull & East Yorkshire Hospitals NHS Trust, Castle Road, Hull, HU16 5JQ, United Kingdom. Faculty of Science and Engineering, University of Hull, Cottingham Road, Hull, HU6 7RX, United Kingdom.
[Ti] Título:A method to incorporate the effect of beam quality on image noise in a digitally reconstructed radiograph (DRR) based computer simulation for optimisation of digital radiography.
[So] Source:Phys Med Biol;62(18):7379-7393, 2017 Sep 01.
[Is] ISSN:1361-6560
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The use of computer simulated digital x-radiographs for optimisation purposes has become widespread in recent years. To make these optimisation investigations effective, it is vital simulated radiographs contain accurate anatomical and system noise. Computer algorithms that simulate radiographs based solely on the incident detector x-ray intensity ('dose') have been reported extensively in the literature. However, while it has been established for digital mammography that x-ray beam quality is an important factor when modelling noise in simulated images there are no such studies for diagnostic imaging of the chest, abdomen and pelvis. This study investigates the influence of beam quality on image noise in a digital radiography (DR) imaging system, and incorporates these effects into a digitally reconstructed radiograph (DRR) computer simulator. Image noise was measured on a real DR imaging system as a function of dose (absorbed energy) over a range of clinically relevant beam qualities. Simulated 'absorbed energy' and 'beam quality' DRRs were then created for each patient and tube voltage under investigation. Simulated noise images, corrected for dose and beam quality, were subsequently produced from the absorbed energy and beam quality DRRs, using the measured noise, absorbed energy and beam quality relationships. The noise images were superimposed onto the noiseless absorbed energy DRRs to create the final images. Signal-to-noise measurements in simulated chest, abdomen and spine images were within 10% of the corresponding measurements in real images. This compares favourably to our previous algorithm where images corrected for dose only were all within 20%.
[Mh] Termos MeSH primário: Simulação por Computador
Processamento de Imagem Assistida por Computador/normas
Mamografia/normas
Imagens de Fantasmas
Intensificação de Imagem Radiográfica/normas
Tomografia Computadorizada por Raios X/normas
[Mh] Termos MeSH secundário: Algoritmos
Seres Humanos
Mamografia/métodos
Intensificação de Imagem Radiográfica/métodos
Processamento de Sinais Assistido por Computador
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1088/1361-6560/aa81fb


  7 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457023
[Au] Autor:Sankatsing VDV; van Ravesteyn NT; Heijnsdijk EAM; Looman CWN; van Luijt PA; Fracheboud J; den Heeten GJ; Broeders MJM; de Koning HJ
[Ad] Endereço:Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
[Ti] Título:The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.
[So] Source:Int J Cancer;141(4):671-677, 2017 08 15.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Long-term follow-up data on the effects of screening are scarce, and debate exists on the relative contribution of screening versus treatment to breast cancer mortality reduction. Our aim was therefore to assess the long-term effect of screening by age and time of implementation. We obtained data on 69,630 breast cancer deaths between 1980 and 2010 by municipality (N = 431) and age of death (40-79) in the Netherlands. Breast cancer mortality trends were analyzed by defining the municipality-specific calendar year of introduction of screening as Year 0. Additionally, log-linear Poisson regression was used to estimate the turning point in the trend after Year 0, per municipality, and the annual percentage change (APC) before and after this point. Twenty years after introduction of screening breast cancer mortality was reduced by 30% in women aged 55-74 and by 34% in women aged 75-79, compared to Year 0. A similar and significant decrease was present in municipalities that started early (1987-1992) and late (1995-1997) with screening, despite the difference in availability of effective adjuvant treatment. In the age groups 55-74 and 75-79, the turning point in the trend in breast cancer mortality was estimated in Years 2 and 6 after the introduction of screening, respectively, after which mortality decreased significantly by 1.9% and 2.6% annually. These findings show that the implementation of mammography screening in Dutch municipalities is associated with a significant decline in breast cancer mortality in women aged 55-79, irrespective of time of implementation.
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico por imagem
Neoplasias da Mama/mortalidade
Mamografia/métodos
Programas de Rastreamento/métodos
[Mh] Termos MeSH secundário: Adulto
Distribuição por Idade
Idoso
Detecção Precoce de Câncer
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Mortalidade/tendências
Países Baixos/epidemiologia
Análise de Regressão
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.30754


  8 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29428007
[Au] Autor:Levinsohn E; Altman M; Chagpar AB
[Ti] Título:Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ.
[So] Source:Am Surg;84(1):1-6, 2018 Jan 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ductal carcinoma in situ (DCIS) is a premalignant condition, whose incidence is increasing in the current era of widespread screening mammography. While eminently treatable, there are innumerable controversies that surround this disease in terms of its diagnosis and treatment. We discuss these issues and review the data to date regarding this condition which affects roughly 20 per cent of all patients presenting with breast cancer.
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Neoplasias da Mama/terapia
Carcinoma Intraductal não Infiltrante/diagnóstico
Carcinoma Intraductal não Infiltrante/terapia
Mamografia
[Mh] Termos MeSH secundário: Detecção Precoce de Câncer
Feminino
Seres Humanos
Mamografia/métodos
Programas de Rastreamento
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180212
[St] Status:MEDLINE


  9 / 26835 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424511
[Au] Autor:Maffuz-Aziz A; Labastida-Almendaro S; Sherwell-Cabello S; RuvalcabaLimón E; Domínguez-Reyes CA; Tenorio-Torres JA; Rodríguez-Cuevas S
[Ti] Título:[Breast Cancer Survival: Clinical andPathological Prognostic Factors Analysis].
[Ti] Título:Supervivencia de pacientes con cáncer de mama. Análisis por factores pronóstico, clínicos y patológicos..
[So] Source:Ginecol Obstet Mex;84(8):498-506, 2016 08.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Background: Breast cancer is the leading cause of cancer death in women in Mexico, is a heterogeneous disease, and knowledge of prognostic factors are critical in making treatment decisions. Objetive: determine the overall survival (OS) and disease-free survival (DFS) at 5 years, analyzed by risk groups. Material and methods: Patients diagnosed with breast treated at the Institute of Breast Diseases FUCAM from July 2005 to December 2014 were included. Simple frequencies were used for analysis of the general characteristics, and 5- year OS and DFS were analyzed using Kaplan-Meier curves. A subset analysis of the clinical stage and comparing survival in those patients diagnosed by mammography screening program was performed. Results: 4,902 patients with breast cancer were included, general clinical and pathological features are described and 3,762 patients were included for analysis of 5-year OS and DFS. The average age at diagnosis was 53.7 years; 13.3% were <40 years, which deleteriously reflects on the supervivencia global 76 vs 84% in >40. At diagnosis predominated locally advanced stages (45%), OS and DFS at 5 years was 96.8 ± 0.6% and 93.4%±0.9 respectively for early stages, 74.6 ± 1.7% and 68.7 ± 2% for locally advanced and 35.9 ± 5.1% and 37.4 ± 10.3% for metastatic tumors. Women diagnosed in the screening program had significantly better OS and DFS compared with symptomatic patients (95 and 93% vs 79 and 77%). For biological subtypes, OS and DFS was 89 and 84% for luminal, 81 and 81% for luminal Her +, 74 and 78% for pure Her 2, and 69 and 73% for triple negative. Conclusion: Knowledge of the prognostic factors that affect survival of patients with breast cancer is essential for categorizing risk groups and to individualize treatment in order to improve life expectancy.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Mamografia/métodos
Programas de Rastreamento/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias da Mama/diagnóstico
Intervalo Livre de Doença
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Meia-Idade
Estadiamento de Neoplasias
Prognóstico
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  10 / 26835 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29368825
[Au] Autor:Davisson L
[Ti] Título:USPSTF Breast Cancer Screening Guidelines.
[So] Source:W V Med J;112(6):29-31, 2016 Nov-Dec.
[Is] ISSN:0043-3284
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Neoplasias da Mama/prevenção & controle
Ginecologia/normas
Mamografia
Obstetrícia/normas
Radiologia/normas
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias da Mama/diagnóstico por imagem
Detecção Precoce de Câncer
Feminino
Ginecologia/estatística & dados numéricos
Seres Humanos
Mamografia/efeitos adversos
Mamografia/métodos
Meia-Idade
Obstetrícia/estatística & dados numéricos
Guias de Prática Clínica como Assunto
Padrões de Prática Médica
Valor Preditivo dos Testes
Radiologia/estatística & dados numéricos
Sensibilidade e Especificidade
Sociedades Médicas/normas
Estados Unidos
West Virginia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE



página 1 de 2684 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde